PDF, Patent Landscape Report on Atazanavir - WIPO

Atazanavir example, the period between chemical naming and routine use of the clinicalname is from 1995 to at least 2001. It is this gap that is challenging for the searcher to fillbecause the search strategies using “pre-clinical” chemical names are more difficult todevise and use. We will return to this issue in Chapter 4.If the SPC approach fails to yield data because of the age of the drug or other factors, thereare some alternatives. If the drug is still under patent protection, the relevant patents maybe listed in the US FDA Orange Book 4 . The information may also be available fromcommercial products such as Thomson Reuters Pharma®Another more laborious approach is to first find patents by the owner of the drug thatmention the clinical name, and then perform a backward citation analysis to find the earliestpredecessor document that covers the composition. This invention may or may not havebeen assigned to the owner at the time of its publication, but US reassignment andINPADOC legal status fields may clarify the chain of ownership.4 http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm8